ロード中...
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma
Secondary malignancies due to alkylating agents or topoisomerase II inhibitors are a concern in patients treated for primary brain tumors of the nervous system. Myelosuppression is the dose-limiting toxic effect of the alkylating agent temozolomide; reversible hematologic toxicity consisting mainly...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3770207/ https://ncbi.nlm.nih.gov/pubmed/23685934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318297eea6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|